Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,303Revenue (TTM) $M27.4Net Margin (%)-404.0Altman Z-Score0.4
Enterprise Value $M1,258EPS (TTM) $-4.4Operating Margin %-383.2Piotroski F-Score4
P/E(ttm)--Beneish M-Score-5.0Pre-tax Margin (%)-401.5Higher ROA y-yN
Price/Book16.910-y EBITDA Growth Rate %--Quick Ratio2.7Cash flow > EarningsY
Price/Sales45.45-y EBITDA Growth Rate %--Current Ratio2.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-51.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-110.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M34.3ROIC % (ttm)-263.5Gross Margin Increase y-yY

Gurus Latest Trades with ZGNX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ZGNX is held by these investors:



ZGNX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Galer Bradley S.EVP/Chief Medical Officer 2017-12-13Buy1,346$36.593.99view
HAWLEY ROGERDirector 2017-12-11Sell131,370$36.733.59view
PERCEPTIVE LIFE SCIENCES MASTE10% Owner 2017-10-03Buy300,000$37.51.47view
PERCEPTIVE LIFE SCIENCES MASTE10% Owner 2017-09-29Buy222,055$32.8315.9view
PERCEPTIVE LIFE SCIENCES MASTE10% Owner 2017-06-30Buy175,653$14.45163.32view
TANNENBAUM RENEE PDirector 2017-03-16Buy5,000$11245.91view
HAWLEY ROGERDirector 2015-12-15Buy10,000$13.74176.93view
HAWLEY ROGERDirector 2015-12-15Buy10,000$13.74176.93view
TANNENBAUM RENEE PDirector 2015-12-03Buy5,000$15.4147.08view
HAWLEY ROGERDirector 2015-06-16Buy6,250$12.72199.14view

Press Releases about ZGNX :

Quarterly/Annual Reports about ZGNX:

News about ZGNX:

Articles On GuruFocus.com
Analysis: Positioning to Benefit within FleetCor Technologies, Zogenix, BioTelemetry, Modine Manufac Jan 04 2018 
Zogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase 3 Clinical Trial of ZX00 Dec 04 2017 
Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome Nov 29 2017 
Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome Nov 29 2017 
Zogenix to Participate in the Global Mizuho Investor Conference 2017 Nov 29 2017 
Zogenix to Present at Stifel 2017 Healthcare Conference Nov 14 2017 
Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results Nov 07 2017 
Zogenix to Release Third Quarter 2017 Financial Results and Host Conference Call and Webcast on Nove Oct 31 2017 
Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy Oct 16 2017 
Largest Insider Trades of the Week Oct 06 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK